Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q4 FY21 results · Jan–Mar 2021
Gufic Biosciences reported revenue from operations of ₹131.93 crore (up 61.7% from Q4 FY20) and net profit of ₹12.87 crore (up 172.5% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a standalone basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 131.93 | 81.59 | +61.7% | 144.41 | −8.6% |
| Other income | 0.66 | 1.13 | −41.8% | 0.60 | +10.0% |
| Total income | 132.58 | 82.72 | +60.3% | 145.01 | −8.6% |
| Profit before tax | 17.05 | 6.07 | +180.8% | 18.17 | −6.2% |
| Net profit for the period | 12.87 | 4.72 | +172.5% | 13.18 | −2.4% |
| EPS, basic (₹) | 1.33 | 0.61 | not comparable | 1.69 | not comparable |
| Net margin (%) | 9.8 | 5.8 | 9.1 |
Standalone
- Filed with BSE
- 05 Jun 2021, 17:23 IST
- Board meeting
- 04 Jun 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE